Results 11 to 20 of about 648 (164)

Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility? [PDF]

Pharmaceuticals, 2020
Fumaric acid esters (FAEs) are small molecules with anti-oxidative, anti-inflammatory and immune-modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing ...
Stephanie Kourakis, Cara A. Timpani, Judy B. de Haan, Nuri Gueven, Dirk Fischer, Emma Rybalka   +5 more
doaj   +4 more sources

Descriptive Analysis of Patients Treated with Diroximel Fumarate and Dimethyl Fumarate-A Real-Life Experience. [PDF]

J Pers Med
Background: Dimethyl fumarate (DMF) and diroximel fumarate (DRF) are two treatments used for multiple sclerosis (MS) that have been shown to be effective in controlling MS patients. DRF was introduced in 2019 with the aim of decreasing the gastrointestinal side effects caused by DMF. Few real-life studies verify the data provided in the clinical trials.
Blanco-Ruiz M, Sánchez-Rodríguez B, Ruiz-Franco ML, Molina Cuadrado E, Sierra García F, Muñoz Fernández C.   +5 more
europepmc   +2 more sources

Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: Results from the randomized, double-blind, phase III EVOLVE-MS-2 study [PDF]

CNS Drugs, 2020
BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF).
et al.,, Naismith, Robert T
core   +3 more sources

Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study [PDF]

Mult Scler, 2020
BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing-remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield bioequivalent exposure to the active metabolite monomethyl fumarate; thus ...
et al,, Naismith, Robert T
core   +3 more sources

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study [PDF]

Neurology and Therapy
Introduction In EVOLVE-MS-1 (NCT02634307), mean absolute lymphocyte count (ALC) on diroximel fumarate (DRF) declined from baseline by approximately 28% in year 1, then stabilized, similar to ALC decline observed with dimethyl fumarate (DMF).
Barry A. Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P. Mendoza, James B. Lewin, Sai L. Shankar   +12 more
doaj   +2 more sources

Comparative activity of dimethyl fumarate derivative IDMF in three models relevant to multiple sclerosis and psoriasis

FEBS Open Bio
Dimethyl fumarate (DMF) is an anti‐inflammatory and immunoregulatory medication used to treat multiple sclerosis (MS) and psoriasis. Its skin sensitization property precludes its topical use, which is unfortunate for the treatment of psoriasis ...
Yulin He, Guiyi Gong, Geovani Quijas, Simon Ming‐Yuen Lee, Ratan K. Chaudhuri, Krzysztof Bojanowski   +5 more
doaj   +2 more sources

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence. [PDF]

Neurol Ther, 2021
Persistence to multiple sclerosis (MS) disease-modifying therapy is fundamental for maximal treatment outcomes. Diroximel fumarate (DRF) is approved in the USA for relapsing MS. Following oral administration, DRF is metabolized to monomethyl fumarate, the active metabolite of dimethyl fumarate (DMF).
Liseno J, Lager B, Miller C, Shankar SL, Mendoza JP, Lewin JB.   +5 more
europepmc   +4 more sources

Diroximel Fumarate Acts Through Nrf2 to Attenuate Methylglyoxal-Induced Nociception in Mice and Decrease ISR Activation in DRG Neurons. [PDF]

Diabetes
Diabetic neuropathic pain is associated with elevated plasma levels of methylglyoxal (MGO). MGO is a metabolite of glycolysis that causes pain hypersensitivity in mice by stimulating the phosphorylation of eukaryotic initiation factor 2α (p-eIF2α) and subsequently activating the integrated stress response (ISR).
Yousuf MS, Mancilla Moreno M, Woodall BJ, Thakur V, Li J, He L, Arjarapu R, Royer D, Zhang J, Chattopadhyay M, Grace PM, Price TJ.   +11 more
europepmc   +3 more sources

New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series. [PDF]

Mult Scler
Lymphopenia is a known adverse effect in patients with relapsing multiple sclerosis (RMS) treated with fumaric acids. We present a case series of four patients diagnosed with RMS with prolonged lymphocyte stability on dimethyl fumarate for over 1 year who developed significant lymphopenia after transitioning to diroximel fumarate.
Schneider M, Kramer J, Banks A, Moses H.
europepmc   +3 more sources

Evolving Patterns of Initial RRMS Treatment in Finland (2013-2022): Insights From a Nationwide Multiple Sclerosis Register [PDF]

Brain and Behavior, Volume 15, Issue 2, February 2025.
Background: The treatment of relapsing-remitting multiple sclerosis (RRMS) is changing. There are limited data about initial treatment of RRMS in Finland.
Ahvenjärvi, Henrik, Autio, Henri, Jokinen, Elina, Krüger, Johanna, Portaankorva, Anne M, Ryytty, Mervi, Soilu-Hänninen, Merja, Viitala, Matias   +7 more
core   +3 more sources